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Abstract: Growing evidence suggests that the activation of the immune/inflammatory 
system may be associated with depression pathogenesis and, in line with this 
observation, several studies mainly focused on pro-inflammatory cytokines reported 
that antidepressant drugs have immunoregulatory effects. However, given the 
complexity of the inflammatory response, which implies the integration of different 
mechanisms triggered by various systems, the aim of the present work was to assess 
the anti-inflammatory properties of the antidepressant agomelatine with an unbiased 
genome-wide approach by using the microarray technique. Specifically, we analyzed 
the gene expression profile of the ventral hippocampus, a cerebral area relevant for 
depression, of adult rats chronically treated with the antidepressant before to receive a 
systemic injection of lipopolysaccharide (LPS) in comparison with animals treated 
with saline. To this aim, adult male Sprague-Dawley rats received agomelatine or 
vehicle for 21 days before being challenged with an acute injection of LPS or saline 
16 h after the last drug administration. Animals were sacrificed 2 h after the immune 
challenge and the ventral hippocampus was dissected and processed for RNA 
extraction. Transcriptomic analysis was performed using Affymetrix® Array and the 
results were analyzed with Partek Genomics Suite and with Ingenuity Pathway 
Analyses software. We found that LPS administration induced the transcription of 284 
genes mainly associated with pathways related to inflammation. Conversely, chronic 
treatment with agomelatine alone modulated 105 transcripts belonging to different 
pathways in saline-treated rats, like the phospolipase C and the CXCR4 pathways. 
Moreover, the drug was able to prevent the LPS-induced modulation of 91 genes with 
respect to the control group and of 52 genes with respect to animals treated only with 
LPS. An intersection analysis between these two lists of genes led to the identification 
of some transcripts induced by LPS on which agomelatine has the larger effect of 
normalization. In summary, by using a genome-wide approach, we have highlighted 
the transcriptional profile of a chronic treatment with agomelatine both at basal state -
identifying genes and pathways related to the basal effects of the antidepressant- and 
in condition of acute inflammation - identifying genes and pathways associated to its 
anti-inflammatory properties. These genes/pathways might represent potential new 
targets for pharmacological intervention of depression associated to inflammation. 
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